

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2021/224354 A1**

(43) International Publication Date  
11 November 2021 (11.11.2021)

(51) International Patent Classification:

*A61K 31/41* (2006.01) *A61K 31/403* (2006.01)  
*A61K 31/549* (2006.01) *A61K 31/405* (2006.01)  
*A61P 7/10* (2006.01) *A61K 31/4178* (2006.01)  
*A61P 9/00* (2006.01) *A61K 31/4704* (2006.01)  
*A61P 9/12* (2006.01) *A61K 31/567* (2006.01)  
*A61K 9/00* (2006.01) *A61K 35/74* (2015.01)  
*A61K 9/12* (2006.01) *A61K 38/00* (2006.01)  
*A61K 31/185* (2006.01) *A61K 38/05* (2006.01)  
*A61K 31/255* (2006.01) *A61K 45/06* (2006.01)  
*A61K 31/401* (2006.01)

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/061917

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

05 May 2021 (05.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20305447.3 06 May 2020 (06.05.2020) EP

(71) Applicants: **QUANTUM GENOMICS** [FR/FR]; 33, rue Marbeuf, 75008 PARIS (FR). **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE** [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel Ange, 75016 PARIS (FR). **COLLEGE DE FRANCE** [FR/FR]; 11, place Marcelin Berthelot, 75005 PARIS (FR).

(72) Inventors: **BALAVOINE, Fabrice**; 48, rue de Vouillé, 75015 PARIS (FR). **LLORENS-CORTES, Catherine**; 9, avenue de la Promenade, 91140 BURES SUR YVETTE (FR). **MARC, Yannick**; 5, rue des Remises, 94100 SAINT-MAUR-DES-FOSSES (FR).

(74) Agent: **CABINET BECKER ET ASSOCIES**; 25, rue Louis le Grand, 75002 PARIS (FR).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: PHARMACEUTICAL COMBINATION COMPRISING A BRAIN AMINOPEPTIDASE A INHIBITOR, A DIURETIC AND A BLOCKER OF THE SYSTEMIC RENIN-ANGIOTENSIN SYSTEM

(57) Abstract: The present invention relates to a pharmaceutical combination comprising (i) fribastat, (ii) a diuretic and (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors (ACEIs) and angiotensin II receptor type 1 (AT1R) antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.

WO 2021/224354 A1